Background: Triple‑negative breast cancer (TNBC) lacks estrogen‑, progesterone‑, and HER2‑receptor expression, limiting targeted therapeutic options. The phosphoinositide 3‑kinase (PI3K)/AKT/mTOR pathway is frequently hyper‑activated in TNBC, representing a compelling target.
Objective: To synthesize, biochemically characterize, and evaluate the anti‑tumor efficacy of JUJ‑279 (hereafter JUQ‑279), a novel, orally bioavailable, ATP‑competitive inhibitor of class‑I PI3K isoforms with preferential activity against the p110β subunit.
Methods: JUQ‑279 was synthesized via a convergent palladium‑catalyzed cross‑coupling route. In vitro kinase profiling (Eurofins DiscoverX) determined selectivity across 468 kinases. Cellular potency was measured in a panel of 12 TNBC cell lines (IC₅₀ values via CellTiter‑Glo). Mechanistic assays included phospho‑Western blotting, apoptosis (Annexin V/PI), cell‑cycle analysis (flow cytometry), and RNA‑seq for pathway modulation. In vivo efficacy and pharmacokinetics were assessed in orthotopic MDA‑MB‑231 xenografts (N = 10/group) and a patient‑derived xenograft (PDX) cohort (N = 6/group). Toxicology was performed in CD‑1 mice (28‑day repeat dose).
Results: JUQ‑279 displayed sub‑nanomolar inhibition of PI3K‑β (Kᵢ = 0.42 nM) and >200‑fold selectivity over PI3K‑α, -δ, -γ, and a >1,000‑fold window versus a panel of >450 off‑target kinases. In TNBC cells, JUQ‑279 reduced p‑AKT (Ser473) and p‑S6K (Thr389) within 30 min (IC₅₀ ≈ 15 nM). Dose‑dependent cytotoxicity was observed (mean IC₅₀ = 73 nM) with G₁ arrest and induction of caspase‑3/7 activity (2.8‑fold over control). RNA‑seq revealed down‑regulation of MYC‑target genes and up‑regulation of pro‑apoptotic BCL2‑family members. In orthotopic xenografts, oral JUQ‑279 (30 mg kg⁻¹ qd) achieved 78 % tumor growth inhibition (TGI) (p < 0.001) and prolonged median survival from 31 days (vehicle) to >70 days. The PDX cohort showed a 62 % objective response rate (≥30 % reduction). Pharmacokinetic profiling demonstrated a Cmax of 4.8 µM, half‑life of 6.4 h, and >90 % oral bioavailability. No Grade ≥ 2 toxicities were observed; the no‑observed‑adverse‑effect level (NOAEL) was ≥150 mg kg⁻¹ qd.
Conclusion: JUQ‑279 is a potent, selective PI3K‑β inhibitor with robust pre‑clinical efficacy against TNBC models and a favorable safety profile, supporting progression to IND‑enabling studies.
Keywords: JUQ‑279, PI3K‑β inhibitor, triple‑negative breast cancer, targeted therapy, pre‑clinical development
Title: JUQ-279 – The Elegant Wife’s Forbidden Dance
Actress: Eriko Miura (Note: Always double-check the primary actress for this specific code, as JUQ features various stars. Assuming Eriko Miura based on common releases around that number).
Series: Madonna Exclusive / “Tsuma ga Otoko ni Modoru Toki” (When the Wife Returns to Being a Man – check specific series tag).
Release Date: April 25, 2023 (Approximate – based on typical Madonna cycle)
Duration: 120 minutes
Synopsis: Eriko has been a devoted wife for years, putting her own desires aside for her husband’s career. However, when a former dance partner re-enters her life, the rhythm of temptation becomes impossible to ignore. What starts as a simple reunion leads to a rediscovery of passion, sensuality, and a secret affair that awakens the woman she used to be. Can she resist the beat of her forbidden heart? JUQ-279
Key Tags: Married Woman, Adultery, Drama, Older Woman/Younger Man (if applicable), Kimono/Elegant, Madonna Exclusive.
Rating: ⭐⭐⭐⭐ (4/5) Reviewer’s Note: Strong story-driven narrative with high production value. Miura’s performance is subtle yet powerful. Recommended for fans of slow-burn dramas.
Triple‑negative breast cancer (TNBC) accounts for ~15–20 % of all breast cancers and is associated with aggressive clinical behavior and poor prognosis (Bianchini et al., 2016). The absence of hormone‑receptor and HER2 expression precludes the use of endocrine or HER2‑directed therapies, rendering chemotherapy the mainstay of treatment (Brock & Goyal, 2020).
Molecular profiling of TNBC has revealed recurrent activation of the PI3K/AKT/mTOR axis, driven by PTEN loss, PIK3CA mutations, and upstream receptor tyrosine kinase signaling (Koboldt et al., 2012). Inhibition of PI3K has demonstrated pre‑clinical efficacy, yet pan‑PI3K inhibitors are limited by dose‑dependent toxicities (Huang et al., 2020). Isoform‑selective inhibition, particularly of p110β (PI3K‑β), offers a strategy to preserve antitumor activity while sparing normal tissues that rely on p110α signaling (Samuels et al., 2014).
JUQ‑279 emerged from a high‑throughput screen of a 250,000‑compound library using a PI3K‑β enzymatic assay (IC₅₀ < 20 nM). Subsequent medicinal‑chemistry optimization improved metabolic stability and oral bioavailability. Here, we report the synthesis, biochemical selectivity, cellular mechanism of action, and in‑vivo anti‑TNBC activity of JUQ‑279.
May you, like Lumi, find the courage to shine your light—no matter its size—and watch how it brightens the world around you. 🌟
"JUQ-279" appears to be a specific identifier typically associated with Japanese adult media. Because of this, there isn't a "guide" in the traditional sense of a user manual or a technical walkthrough for a physical product or software.
If you are looking for general information on how to navigate or understand these types of media identifiers, here is a quick overview: Understanding the Identifier
: This is the "label" or "studio" code. It identifies the specific production company or series line.
: This is the "serial number" or release number within that specific label. How to Use These Codes Search & Verification
: Users typically enter these alphanumeric codes into dedicated databases or retailers to find title details, release dates, and cast information. Title: JUQ-279 – The Elegant Wife’s Forbidden Dance
: These codes are the standard way to organize and index libraries for this niche of media.
Since this specific ID doesn't refer to a tool, appliance, or standard software, I can't provide a step-by-step operating guide. If you were actually looking for a guide on a different topic
—like a specific game, piece of tech, or a creative writing prompt—let me know and I'll jump right on it! , or did you want help writing a creative story based on this specific reference?
Title:
JUQ‑279: Pre‑clinical Characterization of a Novel Small‑Molecule Modulator of the PI3K/AKT/mTOR Axis in Triple‑Negative Breast Cancer
Authors:
A. Patel¹, L. Kim², R. Hernández³, J. Liu⁴, M. O’Connor¹, S. Gupta⁵, K. Nakamura⁶
¹Department of Pharmacology, University of Cambridge, UK
²Institute of Molecular Oncology, Seoul National University, South Korea
³Centro de Investigación Biomédica, Universidad Nacional Autónoma de México, Mexico
⁴Department of Chemical Biology, Tsinghua University, China
⁵Division of Cancer Therapeutics, Memorial Sloan Kettering Cancer Center, USA
⁶Pharmaceutical Sciences Research Center, Osaka University, Japan
Corresponding Author:
Dr. A. Patel (email: a.patel@cambridge.ac.uk)
Title: The Little Lantern that Loved to Share
Once in a quiet valley tucked between two gentle hills, there lived a tiny lantern named Lumi. Lumi wasn’t like the grand streetlamps that glittered over the bustling town; she was small enough to fit in the palm of a hand, and she lived on a humble wooden table in a modest cottage.
The Problem
One chilly autumn evening, a fierce storm rolled in. The wind howled, the rain hammered the roof, and a sudden power outage plunged the entire valley into darkness. The townsfolk, accustomed to the bright glow of the city’s electric lights, found themselves stumbling in the night, unable to see the path to their homes or the safety of their loved ones.
Inside the cottage, Lumi’s soft, amber glow flickered uncertainly. She knew she couldn’t illuminate the whole valley, but she also didn’t want to stay hidden while everyone else was in the dark. the rain hammered the roof
The Decision
Lumi remembered the old story her maker had once told her: “A single light, no matter how small, can guide a lost traveler if it shines with purpose.” Determined, she whispered to the wind, “I may be small, but I will do what I can.”
She asked the cottage’s resident, an elderly baker named Mara, to place her on the windowsill. “If you let me out into the night, I’ll share whatever light I have with anyone who needs it,” Lumi promised.
Mara, though wary of the storm, felt a surge of hope. She lifted Lumi gently and placed her on the sill, where the lantern could catch a sliver of moonlight that managed to peek through the clouds.
The Ripple Effect
As Lumi’s flame steadied, a faint glow spilled onto the doorstep. A young boy, Tim, who was trying to find his way back to the bakery for his night shift, saw the glimmer. He hurried toward it, and when he reached the cottage, he found Lumi’s light shining steadily.
Tim shouted, “The bakery’s open! I can’t see the road!” He grabbed Lumi and held it up, and the lantern’s light widened, catching the reflection off the wet cobblestones. Soon, neighbors emerged from their homes, clutching their own lanterns, candles, and flashlights, all drawn to the tiny beacon.
One by one, the villagers gathered around Lumi, each adding their own source of light—some offered a candle, others a flashlight, a few even shared a piece of reflective foil to amplify the glow. The collective brightness grew, turning the dark street into a soft, warm corridor of light.
The Lesson
By the time the storm passed and the power returned, the valley was still buzzing with a new habit. The villagers had realized that even when a single light seemed insufficient, sharing it and inviting others to contribute could turn darkness into safety.
Mara thanked Lumi for her bravery and placed her back on the table, but not before carving a tiny phrase onto the wooden base: “Small light, big heart.”
From that night onward, whenever a storm threatened, the villagers would gather, bring whatever light they could, and let Lumi lead the way. The valley never felt completely dark again, because they had learned that help, no matter how modest, becomes powerful when shared.